Back to Results

Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohns Disease V: 05 March 2018

Study category: Digestive Health

Is this Study for You?

Let's Get Started!



Type of Study



University of Colorado Hospital

Principal Investigator
Mark Gerich,  MD

Mark Gerich, MD

Study ID

Protocol Number: 16-2456

More information available at NCT02914561

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers